Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).

Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.

Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Abstract: This invention relates to isolated nucleic acids comprising novel genes of a 20 cM region of human chromosome 11q13.3 and the proteins encoded by these genes. Expression vectors and host cells containing these genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.

Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development and in focal adhesion signaling. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Abstract: An isolated polynucleotide encoding a novel immunoglobulin superfamily member named GP354 is provided. GP354 has a predicted single membrane spanning domain and five immunoglobulin (Ig) domains in the extracellular portion of the protein. The protein structure and tissue distribution of GP354 indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the pancreas and central nervous system (CNS). Provided by the invention are isolated GP354 related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to GP354, cells which produce such antibodies, and related diagnostic and therapeutic methods.

Abstract: An isolated polynucleotide encoding a novel immunoglobulin superfamily member named GP286 is provided. GP286 has a predicted single membrane spanning domain and one immunoglobulin (Ig) domain in the extracellular portion of the protein. The protein structure and tissue distribution of GP286 indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the immune system. Provided by the invention are isolated GP286 related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to GP286, cells which produce such antibodies, and related diagnostic and therapeutic methods.

Abstract: An isolated polynucleotide encoding a novel immunoglobulin superfamily member named PanCAM (also named GP354) is provided. PanCAM has a predicted single membrane spanning domain and five immunoglobulin (Ig) domains in the extracellular portion of the protein. The protein structure and tissue distribution of PanCAM indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the pancreas (especially the beta islets), the pituitary gland, and the central nervous system (CNS). Provided by the invention are isolated PanCAM related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to PanCAM, cells which produce such antibodies, and related diagnostic and therapeutic methods.